tagetlocman • Feb 23, 2015 10:46 PM Flag
I don't care about today. I care about 2 years from now.
what? Are you lost again..
I've been enjoying my sale of ACHN at $16, and watching you SOBs here at OXGN lie to each other over and over, for a dime.
And they sit on their #$%$ in SSF and watch this circus. ~40M shares up to $6 and they let it sink 75%.
As the CFO told us at $3: "our valuation is ridiculous. it should be multiples of this." Let's see it. Today.
The flip side, Mort.
"Forty one percent ($123 billion) of the product sales ($300 billion) reported by Big Pharma in 2013 are no longer protected by patents. It still pays a lot of bills, but it's eroding, and it's not a good business. Someone must deal with this. The leaders will, but not every company has them." fierce biotech 1-02-15
"So, proceed with caution and don’t get caught up in the FOMO (Fear of Missing Out) – focus on quality. One takeaway from 2014: it is often the “expensive” equities that continue to get more expensive; last year, picking down-and-out equities was pretty much a losing approach until the tail end of the year. A “cheaper" version of a great technology is usually cheaper for a reason and the “relative valuation” thesis doesn't often pan out. Additionally, a bad management team can blow up a great story rapidly. Separate the science from the investment, because I don't know any executives who aren't bullish."
That's great. It took 60 days after the stock was dumped on full GOG data release, to publish a pdf with a composite look at more science. Its's a long list of features, without stating one GD benefit. No one gives a damn.
What are you doing to market the company, or partner the programs? No one buys OXGN's capacity to develop this science (the features) past this point. Your investors want to see a focking benefit. That would result by this development effort landing else where. Tomorrow. Talk about those efforts. Do that.
this is the type of agreement Oxigene should earn for years of development of the only non-toxic approach to ovarian cancer treatment.. imo. Antisoma was not effective in ovarian.. the application with the greatest need.
Dafodil..OXGN has several specific licensing potentials
Partner Zybrestat for platinum resistant ovarian cancer; in the U.S. or EU .. or both.
revenue potential for 35,000 patients/yr @ $22,500 cost of chemo plus
Partner Zybrestat for AMD.
See Lucentis sales.
Partner Zybrestat for GINET; in the U.S, the EU or both.
This is a $billion+ application for NVS. Patent expired in 2014.
Partner 4503 for AML; world wide.
A growing, unmet need application as better treatment is developed. $1.2 billion projected
Partner all Zybrestat applications: in the U.S. or EU .. or Both
And they could sell the company. Many potentials in front of increasing patent expirations at big pharma.
Sanofi SA risks losing more than $6.5 billion in revenue from one drug alone. Its long-acting diabetes drug Lantus is one of the largest revenue generators going off patent in 2014.
Sanofi will also be losing Renagel, Fabrazyme, Multaq, and Actonel to the patent cliff in 2014. Sanofi risks losing approximately $8.1 billion in revenue this year.
Novartis AG will see its prescription cancer treatment Gleevec go off patent in 2014, and with it nearly $4.69 billion in revenue. The company will also lose its patents to Sandostatin ($1.59 billion) and Exforge ($1.46 billion).
AZN just hit Roche's ovarian market share with an approval. Roche Holding Ltd. will risk losing more than $7.2 billion in revenue. Rituxan is Roche's only major patent-cliff drug in 2014, but at more than $7 billion, it's a huge loss.
LYNPARZA™ approved by the US food and drug administration for the treatment of advanced ovarian cancer in patients with germline BRCA-mutations
Friday, 19 December 2014
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved LYNPARZA™ (olaparib) capsules (400mg twice daily) as the first monotherapy for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer, who have been treated with three or more prior lines of chemotherapy. Olaparib has been approved under the FDA’s Accelerated Approval programme, based on existing objective response rate and duration of response data. Continued approval for this indication is contingent upon verification of clinical benefit in ongoing confirmatory Phase III trials.
Olaparib is a poly ADP-ribose polymerase (PARP) inhibitor that exploits tumour DNA repair pathway deficiencies to preferentially kill cancer cells. It is the first PARP inhibitor to be approved for patients with germline BRCA-mutated advanced ovarian cancer, as detected by an FDA approved companion diagnostic test, BRACAnalysis CDx™.
The FDA based its approval on a Phase II study comparing Lynparza to a placebo in BRCA-positive patients with a companion study.. who'd relapsed after three rounds of chemotherapy. In the 137-patient study, the drug chalked up a 34% response rate..
Only covers 10-15% of patients..
In addition, mutations in BRCA1 and BRCA2 account for around 15 percent of ovarian cancers overall (3). Breast cancers associated with BRCA1 and BRCA2 mutations tend to develop at younger ages than sporadic breast cancers."
This could be a set up. To set expectations in order to have disappointment again..only to see another catalyst a few days later. A partnership makes more sense.. within days.
I don't believe they rode this into the dirt to sell it for $6 bucks.
vvreb.. you could not be more off base. I wouldn't pss on BBF if he caught on fire.
Regarding the French press release. If true, this is no great bargain for shareholders.
$6.50 is a low value for a pair of drugs with as much potential as OXGN's VDA has to replace chemo in recurrent ovarian cancer, not to mention applications in other indications such as ATC/NSLC/GINET/AMD.
Novartis licensed the worldwide rights to Antisoma's oncology drug AS1404, which is expected to enter late-stage testing as a lung cancer treatment in 2008. Antisoma could receive up to $890 million (445 million pounds) from the deal, which also includes an option for Novartis to licence a backup drug candidate currently in early-stage testing.
Under the terms of the agreement, Novartis will make an upfront payment of $75 million to Antisoma and will be responsible for the management and costs of AS1404's late-stage development. Antisoma will be eligible to receive $380 million in milestone payments related to the development and approval of AS1404 in four oncology indications and one non-oncology indication. Antisoma may also receive sales milestone payments of up to $325 million, and holds an option for the US co-marketing rights. If Novartis exercises its option to acquire the backup compound, Antisoma will also be eligible for up to $110 million in milestone payments.
"This agreement further strengthens our...oncology pipeline by adding a novel mechanism to treat solid tumours," commented David Epstein, CEO of Novartis Oncology. The drug, which may be a first-in-class vascular disrupting agent, showed positive mid-stage results in patients with non-small-cell lung cancer and is also being tested in ovarian and prostate cancers.
This deal was consummated on PII data. OXGN's fostrbretabulin has earned a PIII ovarian cancer trial in the U.S. and possible off label use in the EU with the data from GOG 1861.
- Analysis of GOG 186I Study Shows Benefit in Difficult-to-Treat Platinum-Resistant Patients -
Median PFS was 6.7 months for those on bevacizumab and fosbretabulin compared to 3.4 months for those receiving bevacizumab alone (p=0.01; HR=0.57). The addition of fosbretabulin to bevacizumab treatment increased ORR to 40 percent..
Antisoma S1404 didn't cut it in ovarian cancer:
UK-based cancer drug developer Antisoma says that new data from a Phase II trial of its chemotherapy adjuvant ASA404 (formerly known as AS1404) in the treatment of recurrent, platinum-sensitive ovarian cancer, suggests that the drug provided no benefit in terms of time-to-tumor progression over chemotherapy alone.
Antisoma added that, unlike previous studies (Marketletter October 23, 2006) which suggested that the drug had potential as ovarian cancer treatment, the reported data indicates that one-year survival rates in patients who received ASA404 plus chemotherapy were significantly lower than those seen in the chemotherapy alone arm (74% versus 92%).
The firm, which recently received a $75.0 million payment from Swiss major Novartis under a licensing agreement for ASA404 (Marketletter June 18), said that, based on the findings to date, development of the drug for ovarian cancer indications would not be a priority.
You guys know that if ATC gets through the EMA.. we could have some exceptional circumstances. Off Label use in ovarian would be a possibility.
500,000 ovarian cancer patients now on chemo looking forward to a non-toxic New Year :)
As a rule: NO ONEs, ANY WHERE are surviving chemo + anything. And they suffer heavy ASEs during treatment for the rest of their life.
Zybrestat improves PFS of Avastin alone, used in 70% of ovarian cases, by 97% in platinum resistant patients.
The addition of fosbretabulin to bevacizumab treatment increased ORR to 40 percent (n=10) compared to 12.5 percent (n=8) for bevacizumab. A 300% plus improvement in ORR tumor shrinkage.
Chemo: ORR was at best 12.6% with ChemoTherapy versus 30.9% with BEV-ChemoTherapy
From Aurelia: The ORR was 12.6% with CT versus 30.9% with BEV-CT (18.3 percentage-point difference [95% CI, 9.6 to 27.0]; two-sided χ2 with Schouten correction P